# Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

> **NCT03822117** · PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 111 (actual)

## Conditions studied

- Solid Tumor Malignancy

## Interventions

- **DRUG:** Pemigatinib

## Key facts

- **NCT ID:** NCT03822117
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-17
- **Primary completion:** 2022-03-29
- **Final completion:** 2022-03-29
- **Target enrollment:** 111 (ACTUAL)
- **Why stopped:** A business decision was made to to discontinue further enrollment. There were no safety concerns that contributed to this decision.
- **Last updated:** 2025-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03822117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03822117, "Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03822117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*